Nasdaq
$2.82▲ 2.55%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $27.2MShares out 9.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 1d agoAfter-hours26.10.24 06:248-KKey event#●●●
Edesa Biotech, Inc.
Edesa Biotech has approved significant base salary increases for its CEO, President, and CFO, effective retroactively to July 1, 2026. For the CEO, 90% of the monthly base salary will continue to be issued in the form of fully vested restricted share units.…more
$2.82+2.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Pre-market26.10.15 22:158-KKey event
Edesa Biotech, Inc.
Edesa Biotech has received FDA clearance for its Investigational New Drug (IND) application to conduct a Phase 2 clinical study of EB06 for vitiligo. This approval enables the company to expand patient recruitment into the United States, with topline data anticipated in the fourth quarter of 2027.…more
$2.82+2.55%vs prev closeView filingShare - 10.6After-hours26.10.07 06:054Ownership
Edesa Biotech, Inc.
Edesa Biotech insider Pardeep Nijhawan reported a change in beneficial ownership of securities effective October 5, 2026. This filing serves as the official disclosure of the insider's equity transaction via Form 4.…more
$2.82+2.55%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 22:16#●●●#●●●
Edesa Biotech Receives FDA Clearance for Phase 2 Trial of EB06 for Vitiligo…more
Edesa Biotech has received FDA clearance for its IND application to conduct a Phase 2 clinical trial of EB06 for vitiligo, allowing the company to expand recruitment to the U.S. Patient enrollment in the U.S. is expected to begin next quarter, with topline data anticipated in the fourth quarter of 2027.…more
$2.82+2.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.20Pre-market26.08.20 19:20
●●●●●●●● ●●●●● ●●●●●●
Edesa Biotech shares fell after the company announced a $25 million public stock offering to raise fresh capital. The move has triggered concerns regarding potential share dilution for existing investors.…more
$2.82+2.55%vs prev closeShareBenzinga - 8.20Overnight26.08.20 14:28
●●●●●●●● ●●●●● ●●●●●●
Edesa Biotech has priced a $25 million public offering consisting of 3,870,500 common shares and warrants. This offering will result in shareholder dilution, which is typically viewed as a negative development for existing investors.…more
$2.82+2.55%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report